TimesSquare Capital Management released its third-quarter 2025 investor letter, reporting a 2.26% (gross) and 2.01% (net) return, compared to the Russell 2000 Growth Index’s 12.19% return. All asset classes except fixed income outside the U.S. had positive returns. Check out the fund’s top five holdings for 2025 picks.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) was highlighted in TimesSquare Capital’s letter, with a one-month return of 15.54% and a 79.65% gain over the past 52 weeks. On January 5, 2026, MIRM stock closed at $75.56 per share, with a market cap of $3.905 billion. The company is a biopharmaceutical developer based in California.

TimesSquare Capital’s investor letter mentioned adding Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) to its portfolio in Q3 2025. The company is a commercial-stage biopharma developer focusing on liver disease treatments, with plans to expand its flagship Livmarli for a third indication.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is not among the 30 most popular stocks among hedge funds, but 42 hedge fund portfolios held it at the end of Q3 2025. In the same quarter, MIRM reported $133 million in revenue, showing a nearly 50% year-over-year increase. Consider other AI stocks for greater upside potential.

In another article, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) was featured as one of the best biotech stocks to buy according to Wall Street analysts. Explore hedge fund investor letters from Q3 2025 for more insights from leading investors.

Read more at Yahoo Finance: Should You Invest in Mirum Pharmaceuticals (MIRM)?